Literature DB >> 11249822

Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones.

C C Sanders1.   

Abstract

Resistance to the quinolones almost always arises from the accumulation of mutations in chromosomal genes responsible for the drug targets, permeability, or active efflux. This resistance can be depicted as a stepwise process in which each step, represented by separate mutations, diminishes susceptibility on average 4- to 8-fold. The precise path followed in this stepwise process differs with the quinolone that selects resistance as well as the organism involved. At each step, the influence of each mutation on susceptibility to other quinolones not used in the selection process varies greatly, and a pattern of either cross-resistance or dichotomous resistance may be seen. From an understanding of the stepwise process by which resistance to the quinolones evolves, it is possible to use an 8-fold rule to predict which compounds may provide effective therapy for a given infection and be least likely to select for resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11249822     DOI: 10.1086/319369

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Identifying mutator phenotypes among fluoroquinolone-resistant strains of Streptococcus pneumoniae using fluctuation analysis.

Authors:  Carolyn V Gould; Paul D Sniegowski; Mikhail Shchepetov; Joshua P Metlay; Jeffrey N Weiser
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

2.  Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.

Authors:  Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Mechanism of plasmid-mediated quinolone resistance.

Authors:  John H Tran; George A Jacoby
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-09       Impact factor: 11.205

4.  Mutant Prevention Concentrations of Ciprofloxacin and Levofloxacin and Target Gene Mutations of Fluoroquinolones in Elizabethkingia anophelis.

Authors:  I-Fan Lin; Chung-Hsu Lai; Shang-Yi Lin; Ching-Chi Lee; Nan-Yao Lee; Po-Yu Liu; Chih-Hui Yang; Yi-Han Huang; Jiun-Nong Lin
Journal:  Antimicrob Agents Chemother       Date:  2022-06-16       Impact factor: 5.938

5.  Quinolone and cephalosporin resistance in enteric Fever.

Authors:  Malini Rajinder Capoor; Deepthi Nair
Journal:  J Glob Infect Dis       Date:  2010-09

6.  Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products.

Authors:  James R Johnson; Andrew C Murray; Abby Gajewski; Maureen Sullivan; Paula Snippes; Michael A Kuskowski; Kirk E Smith
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

7.  Analytical profiling of mutations in quinolone resistance determining region of gyrA gene among UPEC.

Authors:  Lesley R Varughese; Meenakshi Rajpoot; Soniya Goyal; Ravinder Mehra; Vinod Chhokar; Vikas Beniwal
Journal:  PLoS One       Date:  2018-01-04       Impact factor: 3.240

8.  Characteristics of Quinolone Resistance in Salmonella spp. Isolates from the Food Chain in Brazil.

Authors:  Bruno R Pribul; Marcia L Festivo; Marcelle S Rodrigues; Renata G Costa; Elizabeth C Dos P Rodrigues; Miliane M S de Souza; Dalia Dos P Rodrigues
Journal:  Front Microbiol       Date:  2017-03-14       Impact factor: 5.640

9.  The mutational landscape of quinolone resistance in Escherichia coli.

Authors:  Kamya Bhatnagar; Alex Wong
Journal:  PLoS One       Date:  2019-11-05       Impact factor: 3.240

10.  Pattern of Drug Resistance in Primary Spinal Tuberculosis: A Single-Center Study From India.

Authors:  Sunil Bhosale; Akil Prabhakar; Sudhir Srivastava; Aditya Raj; Shaligram Purohit; Nandan Marathe
Journal:  Global Spine J       Date:  2020-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.